Elevated CSF angiopoietin-2 correlates with blood-brain barrier leakiness and markers of neuronal injury in early Alzheimer’s disease
暂无分享,去创建一个
Sterling C. Johnson | K. Blennow | O. Okonkwo | S. Love | H. Zetterberg | E. Jonaitis | B. Bendlin | S. Asthana | C. Carlsson | C. V. Van Hulle | S. Johnson | J. Miners | Selvi Ince | OC Okonkwo
[1] F. Gao,et al. Changes in CSF sPDGFRβ level and their association with blood–brain barrier breakdown in Alzheimer’s disease with or without small cerebrovascular lesions , 2023, Alzheimer's Research & Therapy.
[2] A. Sheikh,et al. Alzheimer’s Amyloid β Peptide Induces Angiogenesis in an Alzheimer’s Disease Model Mouse through Placental Growth Factor and Angiopoietin 2 Expressions , 2023, International journal of molecular sciences.
[3] V. Kakkassery,et al. Increased Angiopoietin-1 and -2 levels in human vitreous are associated with proliferative diabetic retinopathy , 2023, PloS one.
[4] F. Sun,et al. Neuroprotective Effect of Angiopoietin2 Is Associated with Angiogenesis in Mouse Brain Following Ischemic Stroke , 2022, Brain sciences.
[5] M. Chopp,et al. Treatment With an Angiopoietin-1 Mimetic Peptide Improves Cognitive Outcome in Rats With Vascular Dementia , 2022, Frontiers in Cellular Neuroscience.
[6] Jun Wang,et al. Dynamic changes of CSF sPDGFRβ during ageing and AD progression and associations with CSF ATN biomarkers , 2022, Molecular Neurodegeneration.
[7] M. Chopp,et al. Treatment with an Angiopoietin‐1 mimetic peptide promotes neurological recovery after stroke in diabetic rats , 2020, CNS neuroscience & therapeutics.
[8] R. Morishita,et al. Insight into the Role of Angiopoietins in Ageing-Associated Diseases , 2020, Cells.
[9] A. Toga,et al. Associations between Vascular Function and Tau PET Are Associated with Global Cognition and Amyloid , 2020, The Journal of Neuroscience.
[10] Wei Jia,et al. Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer’s disease and mild cognitive impairment , 2020, Translational Psychiatry.
[11] Platelet-Derived Growth Factor Receptor Beta , 2020, Definitions.
[12] P. Cortelli,et al. CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia , 2019, Alzheimer's Research & Therapy.
[13] K. Blennow,et al. CSF evidence of pericyte damage in Alzheimer’s disease is associated with markers of blood-brain barrier dysfunction and disease pathology , 2019, Alzheimer's Research & Therapy.
[14] C. Wykoff,et al. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. , 2019, Ophthalmology.
[15] M. S. Sajib,et al. Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology , 2019, Cells.
[16] J. Trojanowski,et al. Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology , 2019, Molecular Neurodegeneration.
[17] A. Fagan,et al. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction , 2018, Nature Medicine.
[18] K. Blennow,et al. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease , 2018, Neurology.
[19] Elin Byman,et al. Amyloid‐beta 1‐40 is associated with alterations in NG2+ pericyte population ex vivo and in vitro , 2018, Aging cell.
[20] Berislav V. Zlokovic,et al. Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders , 2018, Nature Reviews Neurology.
[21] I. Ferrer,et al. YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias , 2017, Molecular Neurodegeneration.
[22] S. Love,et al. Differing associations between Aβ accumulation, hypoperfusion, blood–brain barrier dysfunction and loss of PDGFRB pericyte marker in the precuneus and parietal white matter in Alzheimer's disease , 2017, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[23] K. Plate,et al. Angiopoietin-2-induced blood–brain barrier compromise and increased stroke size are rescued by VE-PTP-dependent restoration of Tie2 signaling , 2016, Acta Neuropathologica.
[24] Nick C Fox,et al. Increased CSF neurogranin concentration is specific to Alzheimer disease , 2016, Neurology.
[25] Seth Love,et al. Cerebrovascular disease in ageing and Alzheimer’s disease , 2015, Acta Neuropathologica.
[26] Arthur W. Toga,et al. Blood-Brain Barrier Breakdown in the Aging Human Hippocampus , 2015, Neuron.
[27] C. Laske,et al. Elevated Angiopoietin-1 Serum Levels in Patients with Alzheimer's Disease , 2012, International journal of Alzheimer's disease.
[28] K. Blennow,et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.
[29] D. Stewart,et al. Increased angiopoietin2 expression is associated with endothelial apoptosis and blood–brain barrier breakdown , 2005, Laboratory Investigation.
[30] H. Hammes,et al. Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. , 2004, Diabetes.
[31] J. LaManna,et al. Angiopoietin-2 and rat brain capillary remodeling during adaptation and deadaptation to prolonged mild hypoxia. , 2002, Journal of applied physiology.
[32] S. Mandriota,et al. Hypoxia-inducible angiopoietin-2 expression is mimicked by iodonium compounds and occurs in the rat brain and skin in response to systemic hypoxia and tissue ischemia. , 2000, The American journal of pathology.
[33] T. Bayer,et al. Endothelial LRP 1 transports amyloid-β 1 – 42 across the blood-brain barrier , 2015 .
[34] P. Grammas,et al. Angiogenic proteins are expressed by brain blood vessels in Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.